Regeneron to Report Fourth Quarter and Full Year 2018 Financial and Operating Results and Host Conference Call and Webcast on February 6, 2019
- Wall Street ends sharply higher, led by surging Dow
- Sanderson Farms (SAFM) Explores Sale - Report
- Amazon (AMZN) in Talks to Acquire Stake in Self-Driving Truck Startup Plus: Report
- Dollar dips after Fed rally, Bitcoin slumps
- 5 Companies Set to Hike Their Dividend Over the Next Few Weeks, 3 Dividend Aristocrats
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
TARRYTOWN, N.Y., Jan. 18, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its fourth quarter and full year 2018 financial and operating results on Wednesday, February 6, 2019, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day.
Conference Call InformationTo access this call, dial (800) 708-4539 (U.S.) or (847) 619-6396 (International). A link to the webcast may be accessed from the 'Investors and Media' page of Regeneron's website at http://investor.regeneron.com/events.cfm. A replay of the conference call and webcast will be archived on the Company's website and will be available for 30 days.
About Regeneron Pharmaceuticals, Inc.Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to seven FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases and rare diseases.
Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, such as VelocImmune® which produces optimized fully-human antibodies, and ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world.
For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.
View original content:http://www.prnewswire.com/news-releases/regeneron-to-report-fourth-quarter-and-full-year-2018-financial-and-operating-results-and-host-conference-call-and-webcast-on-february-6-2019-300781040.html
SOURCE Regeneron Pharmaceuticals, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JMA's 5G XRAN Shines in Department of Defense Debut
- Kaival Brands (OTCQB: KAVL) Reports Second Quarter Revenues of $18.1 million and an additional $41.6 million in consignment-based orders from Grocery Store Warehouse and C-Store Master
- Pam Melroy Sworn in as NASA Deputy Administrator
Create E-mail Alert Related CategoriesPress Releases
Related EntitiesTwitter, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!